Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP6 | P51161 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | GFER | P55789 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18090602 | 0.81 | FABP6 (0.50) | FABP6GSK3BMAPKAPK2HPGDGFER | |
| SCHEMBL13392164 | 0.79 | FABP6 (0.61) | FABP6GSK3BMAPKAPK2HPGDGFER | |
| SCHEMBL19977258 | 0.78 | ALDH1A1 (0.40) | HPGDHSD17B10MAPT | |
| SCHEMBL13392166 | 0.69 | HPGD (0.43) | FABP6HPGDGFERHSD17B10TP53 | |
| SCHEMBL24701389 | 0.68 | TDP1 (0.44) | — | |
| SCHEMBL26009341 | 0.66 | PTGS1 (0.48) | HPGDTP53MAPTSMN1; SMN2 | |
| SCHEMBL19977257 | 0.65 | HTR2A (0.35) | TP53MAPT | |
| SCHEMBL10274616 | 0.65 | ALDH1A1 (0.56) | FABP6GSK3BHSD17B10MAPT | |
| SCHEMBL13092730 | 0.64 | FABP6 (0.57) | FABP6GSK3BMAPKAPK2HPGDHSD17B10 | |
| SCHEMBL24784239 | 0.64 | FABP6 (0.47) | FABP6GSK3BHSD17B10JAK2NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10233156-B2 | 9-membered fused ring derivative | SHIONOGI & CO., LTD. (JP) | 2019-03-19 | — | — | US | disclosed |
| US-20180079727-A1 | 9-MEMBERED FUSED RING DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2018-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180079727-A1 | 9-MEMBERED FUSED RING DERIVATIVE | ACSS2, AGTR2, ACSL3 | FABP6 2548/4885GSK3B 2144/4885MAPKAPK2 1286/4885 |
| US-10233156-B2 | 9-membered fused ring derivative | AGTR2, ACSS2, ACSL3 | FABP6 2770/4885GSK3B 2083/4885MAPKAPK2 1155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.